Evgen Pharma PLC Grant of Options (6621A)
09 June 2016 - 4:00PM
UK Regulatory
TIDMEVG
RNS Number : 6621A
Evgen Pharma PLC
09 June 2016
For immediate release 9 June 2016
Evgen Pharma plc
("Evgen Pharma" or the "Company")
Grant of Options
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces that, on 8 June 2016, David Chadwick, the
Company's Senior Clinical Study Manager, was granted nil cost
options over 53,473 ordinary shares exercisable for a period of ten
years from the date of grant under the Evgen Long Term Incentive
Plan ("LTIP").
The number of nil cost options awarded has been calculated by
reference to the three month weighted average through to the
closing market price on 7 June 2016.
These nil cost options will be subject to the rules of the LTIP
and will vest in proportion to a Total Shareholder Return ("TSR")
between the date of grant and the third anniversary of grant.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20
7466 5000
Dr Stephen Franklin, CEO
www.evgen.com
Northland Capital Partners +44 (0) 20 3861
Limited 6625
Matthew Johnson, Gerry Beaney,
Margarita Mitropoulou (Corporate
Finance)
John Howes, Rob Rees (Corporate
Broking)
+44 (0) 20 7466
Buchanan 5000
Mark Court, Sophie Cowles,
Stephanie Watson
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and is based
in Liverpool, UK, at the Liverpool Science Park. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG. For further information please visit
www.evgen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCAKFDBABKDKAK
(END) Dow Jones Newswires
June 09, 2016 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024